当前位置: 首页 >> 检索结果
1061. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C.
Because the effects of interferon in the presence and absence of cirrhosis are still debated in chronic active hepatitis type non-A, non-B, C (NANB/C), the aim of this study was to determine to what extent the presence of cirrhosis influences the response to interferon.
1062. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis.
Primary sclerosing cholangitis (PSC) is a progressive disease with no accepted effective treatment. Because methotrexate was associated with clinical and histological improvement in two men with PSC, we conducted a prospective trial of methotrexate in PSC.
1063. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.
作者: E J Irvine.;B Feagan.;J Rochon.;A Archambault.;R N Fedorak.;A Groll.;D Kinnear.;F Saibil.;J W McDonald.
来源: Gastroenterology. 1994年106卷2期287-96页
Quality of life (QOL), a subjective index of health perception and function, embraces physical, social, and emotional performance but has not had a prominent role in clinical trials of inflammatory bowel disease (IBD). To test the robustness of the Inflammatory Bowel Disease Questionnaire (IBDQ), a disease-specific QOL index, this study assessed its validity, reliability, and responsiveness during a multicenter trial.
1064. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing?
Prolonged infusions of H2-antagonists are commonly used in intensive care units, although little is known about their antisecretory efficacy beyond the initial 24 hours of dosing. The aim of this study was to assess the antisecretory effects of infusions of ranitidine and omeprazole for a period of 72 hours.
1065. Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups.
作者: E Christensen.;D G Altman.;J Neuberger.;B L De Stavola.;N Tygstrup.;R Williams.
来源: Gastroenterology. 1993年105卷6期1865-76页
The precision of current prognostic models in primary biliary cirrhosis (PBC) is rather low, partly because they are based on data from just one time during the course of the disease. The aim of this study was to design a new, more precise prognostic model by incorporating follow-up data in the development of the model.
1066. Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial.
作者: J Terés.;J Bosch.;J M Bordas.;J C Garcia Pagán.;F Feu.;I Cirera.;J Rodés.
来源: Gastroenterology. 1993年105卷5期1508-14页
Sclerotherapy has been widely recommended as initial treatment for prevention of variceal rebleeding. The present study was aimed at comparing the efficacy of endoscopic sclerotherapy and long-term administration of propranolol in the prevention of rebleeding and long-term survival in patients who had bled from varices.
1068. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency.
作者: W R Treem.;N Ahsan.;B Sullivan.;T Rossi.;R Holmes.;J Fitzgerald.;R Proujansky.;J Hyams.
来源: Gastroenterology. 1993年105卷4期1061-8页
No enzyme replacement therapy exists for patients with congenital sucrase-isomaltase deficiency (CSID). A by-product of the manufacture of baker's yeast is a liquid preparation containing high sucrase activity. The aim of the present study was to investigate the activity and stability of this preparation and its effect on breath hydrogen excretion and gastrointestinal symptoms after sucrose ingestion in 14 patients with CSID.
1069. Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY.
作者: L Pironi.;V Stanghellini.;M Miglioli.;R Corinaldesi.;R De Giorgio.;E Ruggeri.;C Tosetti.;G Poggioli.;A M Morselli Labate.;N Monetti.
来源: Gastroenterology. 1993年105卷3期733-9页
Upper gastrointestinal motility is regulated by the presence of nutrients in the distal gut. The present study evaluated whether lipid-induced ileal brake on gastric emptying (1) can be elicited by low fat concentrations; (2) is a dose-dependent phenomenon; and (3) is related to gastrointestinal peptide release.
1070. Diurnal secretory patterns and tolerance during individually titrated infusions of ranitidine.
Gastric acid secretion in humans shows chronobiological patterns that modify the efficacy of antisecretory agents. The ability of individually titrated ranitidine infusions to overcome circadian patterns of gastric acidity and tolerance during prolonged dosing was assessed.
1071. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B.
作者: M R Brunetto.;M Giarin.;G Saracco.;F Oliveri.;P Calvo.;G Capra.;A Randone.;M L Abate.;P Manzini.;M Capalbo.
来源: Gastroenterology. 1993年105卷3期845-50页
Anti-hepatitis e antigen-positive chronic hepatitis B is a progressive liver disease associated with precore mutant hepatitis B virus (HBV) and poor response to interferon. Therefore, precore mutant HBV may behave as an interferon-resistant virus. The relations between the prevalences of wild-type and precore mutant HBVs in baseline viremias and response to interferon were analyzed.
1072. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C.
作者: S Kakumu.;K Yoshioka.;T Wakita.;T Ishikawa.;M Takayanagi.;Y Higashi.
来源: Gastroenterology. 1993年105卷2期507-12页
Chronic hepatitis C is a common and often progressive liver disease for which interferon alfa therapy widely spreads, but the beneficial response is frequently transient. Ribavirin is a nucleoside analog with a broad spectrum of antiviral action, and we investigated the efficacy of it in patients with chronic active hepatitis C.
1073. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease.
作者: K Ewe.;A G Press.;C C Singe.;M Stufler.;B Ueberschaer.;G Hommel.;K H Meyer zum Büschenfelde.
来源: Gastroenterology. 1993年105卷2期367-72页
The role of azathioprine (AZA) in the treatment of active Crohn's disease (CD) is still controversial. This study examined whether AZA combined with standard prednisolone therapy improved the therapeutic outcome compared with monotherapy with prednisolone.
1075. Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment.
作者: L A Balart.;R Perrillo.;J Roddenberry.;F Regenstein.;K S Shim.;Y S Shieh.;B Taylor.;S Dash.;M A Gerber.
来源: Gastroenterology. 1993年104卷5期1472-7页
Successful treatment of chronic hepatitis C with interferon alfa is frequently followed by relapse. Because loss of hepatitis C viral RNA (HCV-RNA) in serum is not predictive of sustained response, the loss of HCV-RNA in liver as a predictor of sustained response was investigated.
1076. Isosorbide-5-mononitrate versus propranolol in the prevention of first bleeding in cirrhosis.
作者: M Angelico.;L Carli.;C Piat.;S Gentile.;V Rinaldi.;E Bologna.;L Capocaccia.
来源: Gastroenterology. 1993年104卷5期1460-5页
Hemodynamic studies have shown the efficacy of nitrates in reducing portal pressure in cirrhosis. We therefore studied the efficacy of isosorbide-5-mononitrate vs. propranolol in the prevention of first bleeding within a prospective controlled trial.
1077. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study.
作者: M S Khuroo.;M Y Dar.;G N Yattoo.;S A Zargar.;G Javaid.;B A Khan.;M I Boda.
来源: Gastroenterology. 1993年104卷5期1452-9页
Recently, drug treatment and percutaneous drainage have been used successfully when treating hepatic hydatid cysts. Until now, there is no published study comparing the relative safety and efficacy of these two forms of treatment.
1078. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
作者: J W Singleton.;S B Hanauer.;G L Gitnick.;M A Peppercorn.;M G Robinson.;L D Wruble.;E L Krawitt.
来源: Gastroenterology. 1993年104卷5期1293-301页
Mesalamine is released from sulfasalazine in the colon and benefits colonic Crohn's disease. The mesalamine used in this study releases the drug throughout the small bowel and colon. Therefore, this study was designed to detect benefit for Crohn's disease involving the small bowel alone or both the colon and small bowel.
1080. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group.
作者: M Büchler.;P Malfertheiner.;W Uhl.;J Schölmerich.;F Stöckmann.;G Adler.;W Gaus.;K Rolle.;H G Beger.
来源: Gastroenterology. 1993年104卷4期1165-70页
A multicenter controlled study was performed to evaluate the effect of high doses of the low molecular weight protease inhibitor gabexate mesilate on mortality and complications associated with moderate and severe acute pancreatitis.
|